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Membrane bound guanylate cyclases are expressed in rod and cone cells of the vertebrate
retina and mutations in several domains of rod outer segment guanylate cyclase 1 (ROS-
GC1 encoded by the geneGUCY2D) correlate with different forms of retinal degenerations.
In the present work we investigated the biochemical consequences of three point
mutations, one is located in position P575L in the juxtamembrane domain close to the
kinase homology domain and two are located in the cyclase catalytic domain at H1019P and
P1069R. These mutations correlate with various retinal diseases like autosomal dominant
progressive cone degeneration, e.g., Leber Congenital Amaurosis and a juvenile form
of retinitis pigmentosa. Wildtype and mutant forms of ROS-GC1 were heterologously
expressed in HEK cells, their cellular distribution was investigated and activity proﬁles
in the presence and absence of guanylate cyclase-activating proteins were measured.
The mutant P575L was active under all tested conditions, but it displayed a twofold shift
in the Ca2+-sensitivity, whereas the mutant P1069R remained inactive despite normal
expression levels. The mutation H1019P caused the cyclase to become more labile. The
different biochemical consequences of these mutations seem to reﬂect the different
clinical symptoms. The mutation P575L induces a dysregulation of the Ca2+-sensitive
cyclase activation proﬁle causing a slow progression of the disease by the distortion of
the Ca2+-cGMP homeostasis. In contrast, a strong reduction in cGMP synthesis due to
an inactive or structurally unstable ROS-GC1 would trigger more severe forms of retinal
diseases.
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INTRODUCTION
Inherited retinal diseases are caused by a heterogeneous
group of mutations in retinal genes (Perrault et al., 2000;
den Hollander et al., 2008; Athanasiou et al., 2013). Among them
are a large number of genes coding for proteins involved in pho-
totransduction processes in the outer segments of rods and cones.
Genetic heterogeneity is paralleled by diverse phenotypical and
clinical characteristics of retinal degenerations, which are classi-
ﬁed in disorders like cone-rod dystrophies, retinitis pigmentosa,
and leber congenital amaurosis (LCA). These disease forms lead
to a loss of visual function, but they differ in the progression of
speciﬁc visual impairments.
Phototransduction in rods and cones is centered on the light-
triggered hydrolysis of the second messenger cyclic GMP, its
powerful re-synthesis after illumination and its role as a ligand tar-
geting a cyclic nucleotide-gated channel in the plasma membrane
(Pugh and Lamb, 2000; Kaupp and Seifert, 2002; Luo et al., 2008).
Phototransduction is further under control of several negative
feedback loops that are important for recovery of the photore-
sponse from illumination and for adjusting the cell performance to
ambient background light (Fain et al., 2001). One crucial molecu-
lar factor involved in the regulation of phototransduction is Ca2+,
which binds to and dissociates from Ca2+-sensor proteins under
oscillating changes in cytoplasmic Ca2+-concentration [Ca2+].
A multi-protein complex operating at the interface between
changing concentrations of cGMP and [Ca2+] consists of a sen-
sory type membrane-bound guanylate cyclase that is regulated
by guanylate cyclase-activating proteins (GCAPs; Stephen et al.,
2008; Dizhoor et al., 2010; Koch et al., 2010; Koch and Dell’Orco,
2013). So far, mutations in patients suffering from retinal dis-
eases are found in the gene GUCA1A encoding the Ca2+-sensor
GCAP1 and GUCY2D coding for the outer segment guanylate
cyclase type 1 (ROS-GC1) (Kitiratschky et al., 2008; Behnen et al.,
2010; Hunt et al., 2010). Previous research was focused on eluci-
dating the molecular causes and cellular consequences of point
mutations in ROS-GC1 and GCAP1 and in a further step to
test therapeutic strategies involving RNA interference techniques
and transgenic mouse lines (Buch et al., 2011; Jiang et al., 2011;
Boye et al., 2013).
However, disease causing mutations can also point to critical
amino acid positions that determine structure-function relation-
ships in natively folded protein structures and therefore might
help to gain mechanistic insights of protein function and reg-
ulation (Duda et al., 1999a, 2000; Ramamurthy et al., 2001). For
example, a biochemical study onmutations in the so-called dimer-
ization domain of ROS-GC1 correlating with cone-rod dystrophy
recently revealed that this dimerization or linker domain oper-
ates as a Ca2+-sensitive control switch module (Zägel et al., 2013).
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In the present work we tested the biochemical consequences of
three point mutations (Figure 1). The mutation P575L was found
in a family, where clinically affected members suffer from pro-
gressive cone degeneration (Small et al., 2008). The amino acid
substitution is located in the juxtamembrane domain (JMD),
which is a speciﬁc region of sensory GCs upstream of the kinase
homology domain (KHD). H1019P is located in the cyclase cat-
alytic domain (CCD) and patients with this missense mutation
show the typical clinical symptoms of LCA type 1 suffering
from severe visual impairment at birth (Perrault et al., 2000).
Finally, P1069R is also within the CCD and a patient carrying
this mutation was diagnosed with juvenile retinitis pigmentosa
(Booji et al., 2005).
So far, none of these mutations have been investigated on
a molecular level. Two of the main questions are for exam-
ple what the consequences on guanylate cyclase activity are and
which Ca2+-dependent activation proﬁles can be observed in the
presence of GCAPs. These topics are addressed in the present
contribution.
MATERIALS AND METHODS
CLONING AND SITE-DIRECTED MUTAGENESIS OF HUMAN ROS-GC1
CONSTRUCTS
The cDNA of human ROS-GC1 was cloned into the vector
pIRES2-eGFP (Clonetech) exactly as described previously (Zägel
et al., 2013). DNA was prepared by using the DNA puriﬁca-
tion kit of Promega according to manufacturer’s instruction.
The mutant P575L was produced by using the following primers
for PCR ampliﬁcation: 5′-GCTATCCGCCTAGCAACCAAGACG-
3′ (forward) and 5′-CGTCTTGGTTGCTAGGCGGATAGC-3′
(reverse). Site-directed mutagenesis yielding the mutants H1019P
and P1069R was achieved by performing two PCRs each
using the ROS-GC1-WT gene in the pIRES2-eGFP vec-
tor as template. Primers for the PCR were for creat-
ing H1019P: 5′-CCTTACCGCATCCCCGTGAACTTGAG-3′ and
5′-TCAAGAGAACTGGCCCGGCCGC-3′ (forward and reverse
primer, ﬁrst PCR) and 5′-AAAGCTAGCCACCATGACCGCC-
TGCGCCCGCC-3′ and 5′-CTCAAGTTCACGGGGATGCGG-
TAAGG-3′ (forward and reverse primer, secondPCR). P1069Rwas
obtained with 5′-CCCATCCCCAAACGGCCTGACCTG-3′ and
5′-TCAAGAGAACTGGCCCGGCCGC-3′ (forward and reverse
primer in the ﬁrst PCR) and 5′-AAAGCTAGCCACCATGACCGC
CTGCGCCCGCC-3′ and 5′-CAGGTCAGGCCGTTTGGG-
GATGGG-3′ (forward and reverse primer in the second PCR).
The resulting two fragments were used in a further PCR to obtain
a complete mutated ROS-GC1-DNA construct (3320 bp) by
employing the primers 5′-AAAGCTAGCCACCATGACCGCCTG-
CGCCCGCC-3′ and 5′-TCAAGAGAACTGGCCCGGCCGC-3′.
The ﬁnal construct was cut with Nhe I, phosphorylated with
T4 polynucleotide kinase and ligated in the pIRES2-EGFP vec-
tor that was cut by Nhe I/Sma I. Clone products were veriﬁed by
sequencing.
HETEROLOGOUS EXPRESSION OF ROS-GC1 AND GCAPs
WT and mutant forms of ROS-GC1 were expressed in HEK
ﬂip 293 cells. For this purpose cells were cultivated in mini-
mal essential medium under standard conditions as described
FIGURE 1 | Amino acid positions of mutations in ROS-GC1.Topology of
ROS-GC1 domains is indicated as extracellular domain (ECD) corresponding
to the intradiscal region when cyclases are expressed in rod outer
segments, transmembrane domain (TM), JMD, KHD, dimerization domain,
and cyclase catalytic domain (CCD). Numbers correspond to the
unprocessed human sequence.
(Koch and Helten, 2008). After culturing 3–5 × 106 cells were
harvested in 100 μL of a buffer containing 5 mM KCl, 20 mM
MgCl2, and 150 mM phosphate buffer pH 7.2. For transfec-
tion, 5 μg of DNA was added and cells were electroporated with
the CLB system (Lonza). Further treatment of cells and harvest-
ing for subsequent guanylate cyclase assays was done exactly as
described (Zägel et al., 2013). GCAP1 and GCAP2 were expressed
in E. coli and puriﬁed to homogeneity by anion exchange and
size exclusion chromatography as previously reported (Hwang
et al., 2003; Koch and Helten, 2008). Myristoylation of GCAPs
during bacterial expression was accomplished by co-transforming
E. coli cells with N-myristoyl-transferase from yeast and sup-
plementation with myristic acid. To ensure a high degree of
myristoylation of GCAP1, which lacks the consensus site for
yeast N-myristoyl-transferase, we used the D6S-mutant of GCAP1
(Krylov et al., 1999; Hwang et al., 2003). The degree of myris-
toylation of both GCAPs was typically higher than 90% as
checked by using an analytical HPLC run on a reverse-phase
column.
GUANYLATE CYCLASE ASSAY
Recombinant human ROS-GC1 in HEK cell membranes was
measured as described before (Koch and Helten, 2008; Zägel
et al., 2013). In addition to measuring the basal guanylate cyclase
activity we mainly tested two effects of GCAPs on the acti-
vation proﬁle of the cyclase. In a ﬁrst set we added puriﬁed
bovine GCAP1 or GCAP2 at saturating 10 μM to washed HEK
cell membranes and incubated samples at different free [Ca2+]
using a Ca2+-EGTA buffer system. Details of the procedure
have been described in several previous publications (Hwang
et al., 2003; Koch and Helten, 2008; Zägel et al., 2013). Data
were evaluated to obtain the [Ca2+], at which the activation
is half-maximal (IC50). In a second set of guanylate cyclase
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assays we incubated recombinant ROS-GC1 with increasing con-
centrations of GCAP1 and GCAP2 (0–20 μM) for 30 min
under Ca2+-free conditions. GCAPs were liganded with Mg2+
(Peshenko and Dizhoor, 2004) using the same buffer composition
as described (Koch and Helten, 2008). The latter activity mea-
surements yielded apparent afﬁnities (EC50-values) of GCAPs for
WT and mutant ROS-GC1. Activity values were obtained from
at least 3–4 different data sets and were used to calculate the
mean ± standard deviation (SD). A student’s t-test was per-
formed to check for signiﬁcant differences between two sets of
data.
IMMUNOHISTOCHEMISTRY
Localization of ROS-GC1 WT and mutants in HEK cells by
immunoﬂuorescence microscopy was done as described before
using an Olympus ﬂuorescence microscope (Zägel et al., 2013).
The following primary antibodies were used for detection: anti-
ROS-GC1 (1:100; ROS-GC1 (H-225), sc50512, rabbit polyclonal
IgG; Santa Cruz Biotechnology), anti-Na+/K+-ATPase (1:200;
Na+/K+-ATPase, a (H-3), sc-48345, mouse monoclonal IgG2b;
Santa Cruz Biotechnology), and anti-calnexin [1:200; calnexin
(E-10), sc-46669, mouse monoclonal IgG2a; Santa Cruz Biotech-
nology]. Secondary antibodies were donkey anti-rabbit conju-
gated to Fura350 (dilution 1:200) from Invitrogen and goat
anti-mouse conjugated with Dylight594 from Thermo Scientiﬁc,
USA used in a dilution of 1:500. Incubation and washing buffers
were exactly as described (Zägel et al., 2013).
RESULTS AND DISCUSSION
LOCALIZATION OF ROS-GC1 CONSTRUCTS
Previous work has shown that ROS-GC1 can be expressed
heterologously in HEK293 cells in sufﬁcient quantity to allow sub-
sequent biochemical studies (Hwang et al., 2003; Koch and Helten,
2008; Zägel et al., 2013). In HEK293 cells the enzyme was found
to be present in cell membranes and mainly co-localized with the
endoplasmic reticulum. Probing the cells with an anti-ROS-GC1
antibody (Figure 2A, middle panel) and using speciﬁc markers
for the plasma membrane (anti-Na+/K+-ATPase antibody, top
left panel in Figure 2A) and for the endoplasmic reticulum (anti-
calnexin, top right panel) we obtained a staining pattern in the
overlay image (Figure 2A, bottom panels) in agreement with
published results (Peshenko et al., 2008; Zägel et al., 2013). The
localization of all investigated mutants was very similar to the
cellular localization of the WT. Using western blotting we fur-
ther estimated that the amount of ROS-GC1WT and mutants was
nearly the same in a suspension of cells having a similar cell density
(Figure 2B, also Zägel et al., 2013).
BASAL GUANYLATE CYCLASE ACTIVITIES
The mutant P575L exhibited similar basal GC activities as WT
(Figure 3). Activities in the presence of GCAP1 and 2 at satu-
rating [Ca2+] revealed almost no difference between P575L and
WT. However, a difference was observed, when GCAP1 and 2
were incubated with ROS-GC1 at low [Ca2+] (EGTA columns
in Figure 3) resulting in a 25–30% decrease of maximal activity.
FIGURE 2 | Cellular localizationofWTandROS-GC1mutants inHEK293
cells. (A)Cellswere stably transfectedwith humanROS-GC1 constructs and
were probedwith different antibodies; the correspondingROS-GC1 construct
used for transfection is indicated in the corner of the upper left panel.
Anti-Na+/K+-ATPasewas used as plasmamembranemarker (upper left panel,
red staining); anti-calnexin antibodies asmarker for the endoplasmic reticulum
(top right panel, red staining); anti-ROS-GC1 antibody (middle panels, blue
staining); overlay of ROS-GC1 staining andmembrane speciﬁc localization
(lower panels). Secondary antibodieswere indicated in theMethods section.
Visualizationwas done in anOlympus ﬂuorescencemicroscope. Cellswere
ﬁxed eitherwith paraformaldehyde (localization of plasmamembrane) orwith
paraformaldehyde-methanol (endoplasmic reticulum). Scale bar= 10μm.
(B)Western blot of HEK293 cells expressing humanROS-GC1,WT and the
mutants P575L, H1019P, andP1069R. Blotswere probedwith a primary
antibody against ROS-GC1 (GC1#3, dilution 1:2000) and a secondary anti-rabbit
antibody fromDianova (dilution 1:4000) as described (Zägel et al., 2013).
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FIGURE 3 | Guanylate cyclase activities ofWT and the P575L mutant.
Ca2+-bound and Ca2+-free (EGTA) GCAP1 or GCAP2 were added to
HEK293 cell membranes expressing human ROS-GC1 (inset) yielding a
ﬁnal concentration of 10 μM. Ca2+ was either at 33 μM or <10 nM (EGTA).
Assay incubations were performed with equal amounts of WT and mutant
guanylate cyclase in membranes, which was veriﬁed by western blotting
(see Figure 2B). Some error bars are not visible due to the scaling of the
ﬁgure. Differences between data sets were highly signiﬁcant yielding
***P ≤ 0.001, except for P575L; when its basal activity was compared with
the activity in the presence of Ca2+-bound GCAP2, it resulted in**P ≤ 0.01.
In sharp contrast to P575L, the mutant P1069R did not exhibit
any activity, neither in the presence nor in the absence of Ca2+,
EGTA,orGCAPs (data not shown).We also tested activities of cells
transiently expressing the mutant or a stably transfected cell line.
Since the cellular localization of this mutant appeared normal and
was very similar to the active WT and P575L forms (Figure 2A),
we conclude that the lack of GC activity was a consequence of an
impaired catalytic domain.
A special case was observed with the mutant H1019P: we were
unable to obtain consistent activity proﬁles as we did withWT and
the P575L mutant. In some cell batches we observed activation by
GCAP1, but not by GCAP2, whereas in other batches both GCAPs
were able to activate the cyclase or the enzyme was inactive under
all conditions. The large scattering of the results seems to indicate
a general instability of the mutant.
GCAP-MEDIATED ACTIVATION
The key feature among ROS-GC1 properties is the Ca2+-
dependent activation under control of GCAPs. We tested this
activation of P575L by GCAPs and compared it with the WT
activity proﬁle. Representative data sets are shown in Figure 4A
(+GCAP1) and Figure 4B (+GCAP2), a summary of the IC50
values (mean ± SD) is displayed in Table 1. For both Ca2+-sensor
proteins we observed a similar two-fold shift of the IC50 values
to lower [Ca2+], in the presence of GCAP1 from 0.529 (WT)
to 0.270 μM (P575L) and in the presence of GCAP2 from 0.269
μ(WT) to 0.128 μM (P575L).
A shift in the IC50 values had previously been reported for some
autosomal cone dystrophy related mutations that are located in a
so-called “mutation hotspot” region within or near the residue
R838 in the dimerization domain (Duda et al. 1999a, 2000; Wilkie
FIGURE 4 | Ca2+-sensitive activity profiles ofWT and ROS-GC1 mutant
P575L. Guanylate cyclase activities were measured as a function of free
[Ca2+] for samples as indicated (A)WT or P575L, in the presence of 10 μM
GCAP1. (B)WT or P575L, in the presence of 10 μM GCAP2. Incubation
time was 30 min. Activities are normalized to allow comparison of IC50
values ([Ca2+]free at which activity is halfmaximal). Data are representative
of three to four sets of incubations.
et al., 2000; Kitiratschky et al., 2008; Zägel et al., 2013). One rea-
sonable model explaining this observed effect states that the shift
in Ca2+-sensitivity originates from different apparent afﬁnities
of WT and mutant ROS-GC1 for the Ca2+-free form of GCAPs
Table 1 | Summary of IC50 and EC50 values forWT and P575L mutant.
ROS-GC1 IC50 (μM) EC50 (μM)
WT + GCAP1 0.529 ± 0.006 2.93 ± 0.37
WT + GCAP2 0.269 ± 0.009 8.34+ ± 0.36
P575L + GCAP1 0.270* ± 0.018 3.32+ ± 0.39
P575L + GCAP2 0.128 ± 0.014 7.44 ± 1.26
*Six data sets; +two data sets.
Values are the mean ± SD of mainly three to four independent measurements,
if not indicated otherwise.
Frontiers in Molecular Neuroscience www.frontiersin.org February 2014 | Volume 7 | Article 4 | 4
Zägel and Koch Dysfunction of outer segment guanylate cyclase
FIGURE 5 | GCAP-dependency ofWT and P575L to determine apparent
affinities (EC50).WT and mutant P575L (see inset) were incubated with
Ca2+-free (Mg2+-bound) GCAP1 (A) and GCAP2 (B). The amount of cGMP
produced by ROS-GC1 is shown as a function of the GCAP concentration.
Incubation time was 30 min.
(Peshenko et al., 2004). We tested this hypothesis for the P575L
mutant by measuring the GC activities at increasing GCAP con-
centrations (Figure 5). GCAP1 and 2 were Ca2+-free, but they
had Mg2+-bound (Peshenko and Dizhoor, 2004) under the assay
conditions. Apparent afﬁnities expressed as EC50-values differed
only minimally between WT and the P575L mutant and over-
lapped within the measured standard deviations (Table 1). Thus,
we conclude that differences in apparent afﬁnities for GCAPs can-
not account for the observed shifts inCa2+-sensitivity of theP575L
mutant.
STRUCTURE-FUNCTION RELATIONSHIPS
The single point mutation P575L is located in direct C-terminal
neighborhood of a small stretch of 20 amino acids, which was
previously identiﬁed as an essential regulatory and/ or interaction
site in bovine ROS-GC1 for GCAP1 (L559–I578 corresponding to
peptide #34a in Lange et al., 1999). The region is highly conserved
among different species and encompasses also the point mutation
F565S (human sequence) that is linked to LCA type 1 (Perrault
et al., 1996). However, the biochemical consequences of these two
mutations differ signiﬁcantly, since F565S leads to a more than
10-fold lower basal cyclase synthesis rate, but also to a complete
loss of the GCAP1-stimulated GC activity (Duda et al., 1999b).
These biochemical consequences are in contrast to the less severe
effects caused by the P575L mutation.
The position H1019P is located in the short β6-sheet of the
CCD in close vicinity of the β5-sheet that harbors amino acids
R995, C997, L998, and F999, which are critical for binding the
purine ring of theGTP substrate (Tucker et al., 1998). Replacement
of H by P might cause a “kink” of the β6-sheet and therefore
disrupts or destabilize the catalytic center. A mutation of A to P
in α-synuclein for example was reported to have long-range and
short-range effects on the three-dimensional structure including a
decrease of β-sheet content (Wise-Scira et al., 2013). Furthermore,
the position H1019P is also located in the GCAP2 binding site that
was previously narrowed down to the amino acid stretch Y1012-
N1037 in the bovine sequence (Duda et al., 2005; Pettelkau et al.,
2012). In summary, these results might explain the large scattering
of GC activities observed in the in vitro assays.
In our test system the mutation P1069R had the most dra-
matic consequences leading to a completely inactive enzyme.
This position is sandwiched between the binding sites of GCAP2
and S100β (Duda et al., 2002) and we can only speculate that
it might have the function to integrate diverse signals. Further-
more, it seems to be indispensable for the basal catalysis of
ROS-GC1.
CONCLUSION
Inherited retinal disorders can affect visual function in different
manners. In the present study we investigated the biochemical
consequences of three point mutations in the GUCY2D gene,
which cause different forms of visual impairment. The muta-
tion P575L causes a progressive form of cone degeneration in
affected patients, which very often correlates with symptoms of
photophobia, decrease of central vision and impairment of color
vision. Since themutation did not lead to a complete loss of guany-
late cyclase function, cone cells expressing the mutated ROS-GC1
protein very likely maintain key features of photoreceptor phys-
iology. But since the mutation induces a dysregulation of the
Ca2+-sensitive cyclase activation proﬁle, it seems to have long-
term effects in the distortion of the Ca2+-cGMP homeostasis
triggering apoptotic pathways. Similar consequences have been
discussed for GCAP1 mutations correlating with certain forms
of cone-rod dystrophies (Behnen et al., 2010; Hunt et al., 2010).
The other two point mutations that were investigated in the
present study correlate with LCA and a juvenile form of retinitis
pigmentosa. Both mutations have more severe pathological con-
sequences. Typical clinical features are for example an early onset
of the disease in childhood and a strongly reduced or even non-
recordable electroretinogram (Perrault et al., 2000; Booji et al.,
2005). Clinical manifestations of the point mutations appear to
be mirrored in the biochemical properties of the expressed ROS-
GC1 protein as there are: synthesis of cGMP by ROS-GC1 is
either severely disrupted due to protein instability (H1019P) or
completely abolished (P1069R). Thus, light-triggered hydrolysis
of cGMP cannot adequately be balanced by the second photore-
ceptor speciﬁc guanylate cyclase (ROS-GC2, GC-F), which has a
much lower expression level, at least in cone cells (Olshevskaya
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et al., 2002; Baehr et al., 2007). The cGMP level in photorecep-
tor cells would be lower than in non-affected cell. This in turn
would keep a lower number of cyclic nucleotide-gated channels
open in the dark state. Since the cytoplasmic cGMP pool that is
hydrolyzed after illumination is already reduced in the dark, ampli-
tude and kinetics of the photoresponse are expected to be smaller
and faster.
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